55 citations,
April 2010 in “Cancer and Metastasis Reviews” TGFβ's manipulation of inflammation and immune cells affects cancer spread, suggesting new treatment strategies and biomarkers.
9 citations,
July 2002 in “Journal of the European Academy of Dermatology and Venereology” The document concludes that fexofenadine reduces inflammation in chronic hives, cholestyramine helps half of pregnant women with itchy rashes, and relaxing incisions are a good alternative in facial surgery for the elderly.
[object Object] 4 citations,
November 2016 in “Pediatric Clinics of North America” The document explains the difficulty in diagnosing and treating brain diseases caused by the immune system and stresses the need for quick and accurate tests.
1 citations,
August 2023 in “Frontiers in immunology” Traditional Chinese medicinal foods may help manage long-term post-COVID symptoms.
1 citations,
August 2007 in “Indian Journal of Pediatrics” A girl with symptoms like an autoimmune disorder actually had HIV and a fungal infection, which was hard to diagnose and treat, leading to her death.
1 citations,
October 1996 in “Journal of Cutaneous Medicine and Surgery” Gene therapy shows promise for treating skin disorders and cancer, but faces technical challenges.
September 2023 in “Frontiers in medicine” The mTOR signaling pathway is crucial for hair health and targeting it may lead to new hair loss treatments.
April 2023 in “Medizinische Genetik” New research has found 14 genes linked to the risk of developing alopecia areata, improving understanding and treatment options.
TLR3 signaling enhances the immunosuppressive properties of human periodontal ligament stem cells.
August 2017 in “Journal of epidemiological research” Cancer rates are increasing in developed countries, with estrogen, aging, low vitamin D3, and HPV infection as common causes.
375 citations,
July 2006 in “Journal of Investigative Dermatology” Stress can worsen skin and hair conditions by affecting the skin's immune response and hormone levels.
150 citations,
October 2010 in “The American Journal of Pathology” The document concludes that more research is needed to better understand and treat primary cicatricial alopecias, and suggests a possible reclassification based on molecular pathways.
102 citations,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Restoring hair bulb immune privilege is crucial for managing alopecia areata.
5 citations,
May 2023 in “Frontiers in immunology” Environmental factors like diet and vitamin levels, especially Vitamin D, can affect autoimmune diseases differently, with lifestyle changes potentially improving outcomes.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
10 citations,
January 2021 in “Annals of dermatology/Annals of Dermatology” Nivolumab can cause hair loss as a rare side effect.
1 citations,
May 2024 in “International Journal of Molecular Sciences” Adenosine receptors could be promising targets for treating inflammatory skin diseases like psoriasis.
142 citations,
March 2019 in “Molecules/Molecules online/Molecules annual” Cannabinoids may help treat various skin conditions.
14 citations,
September 2021 in “Journal of Inflammation Research” Alopecia areata patients, especially women with nail issues or atopic diseases, are at higher risk for other autoimmune diseases.
2 citations,
September 2022 in “Cytotherapy” Fat-derived stem cells show promise for treating skin issues and improving wound healing, but more research is needed to confirm the best way to use them.
1 citations,
August 2023 in “Biomolecules” Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.
16 citations,
October 2023 in “Molecular cancer” New treatments like nanotechnology show promise in improving skin cancer therapy.
17 citations,
July 1994 in “Journal of Dermatological Science” The cause of alopecia areata is likely a mix of genetics, immune system issues, and environmental factors, with more research needed to understand it fully.
51 citations,
December 2017 in “Skin Appendage Disorders” Stress may trigger hair loss by affecting immune protection in hair follicles.
December 2011 in “InTech eBooks” Systemic corticosteroids can help treat rapidly spreading vitiligo but require more research for safer use.
1 citations,
June 2023 in “Biomolecules & therapeutics” Nitric oxide is important for skin functions and both helps protect against and contributes to skin inflammation and sensitization.
[object Object] 55 citations,
October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.
7 citations,
January 2013 in “The journal of investigative dermatology/Journal of investigative dermatology” T-cell reconstitution after thymus transplantation can cause hair whitening and loss.
42 citations,
April 2021 in “JCI insight” Blocking JAK3 signaling can reverse hair loss from alopecia areata.
May 2024 in “Frontiers in Immunology” This mini-review examines the role of type-2 immunity in type-1-related skin inflammatory diseases, such as alopecia areata (AA), vitiligo, and localized scleroderma (LS). It reveals that while type-1 immunity is traditionally associated with these conditions, type-2 immunity also plays a significant role. In LS, type-2 cytokines like IL-4 and IL-13 are linked to fibrosis, and in AA, elevated type-2 markers suggest involvement in disease pathogenesis. The review highlights the potential of treatments targeting type-2 responses, such as JAK inhibitors and therapies focusing on the IL-4/IL-13 axis, which show promise in specific patient subsets. Further research is needed to understand whether type-2 immunity is protective or detrimental in these diseases, which could improve patient stratification for targeted therapies.